<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Orchid Pharma Limited — News on 6ix</title>
<link>https://6ix.com/company/orchid-pharma-limited</link>
<description>Latest news and press releases for Orchid Pharma Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 23 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/orchid-pharma-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68364d5e78dffbe2df154170.webp</url>
<title>Orchid Pharma Limited</title>
<link>https://6ix.com/company/orchid-pharma-limited</link>
</image>
<item>
<title>Orchid Island Capital Announces First Quarter 2026 Results</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-announces-first-quarter-2026-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-announces-first-quarter-2026-results-1</guid>
<pubDate>Thu, 23 Apr 2026 20:05:00 GMT</pubDate>
<description>VERO BEACH, Fla., April 23, 2026 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced results of operations for the three month period ended March 31, 2026. First Quarter 2026 Results Net loss of $(20.0) million, or $0.11 per common share, which consists of:Net interest income of $57.1 million, or $0.30 per common shareTotal expenses of $7.4 million, or $0.04 per common shareNet realized and unrealized lo</description>
</item>
<item>
<title>Orchid Island Capital to Announce First Quarter 2026 Results</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-to-announce-first-quarter-2026-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-to-announce-first-quarter-2026-results-1</guid>
<pubDate>Tue, 07 Apr 2026 14:04:00 GMT</pubDate>
<description>VERO BEACH, Fla., April 07, 2026 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the first quarter of 2026 following the close of trading on the New York Stock Exchange on Thursday, April 23, 2026. Earnings Conference Call Details An earnings conference call and live audio webcast will be hosted Friday, April 24, 2026, at 10:00 AM ET. Participants can register and rec</description>
</item>
<item>
<title>Orchid Launches Identity Audit to Illuminate the Dark Matter of Enterprise Identity Activity</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-launches-identity-audit-to-illuminate-the-dark-matter-of-enterprise-identity-activity</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-launches-identity-audit-to-illuminate-the-dark-matter-of-enterprise-identity-activity</guid>
<pubDate>Thu, 05 Feb 2026 14:00:00 GMT</pubDate>
<description>Alarming data shows 46% of enterprise identity activity occurs outside centralized IAM visibility Orchid Launches Identity Audit to Illuminate the Dark Matter of Enterprise Identity Activity New "identities" tab, providing an overview of audit insights Orchid Launches Identity Audit to Illuminate the Dark Matter of Enterprise Identity Activity Drill down of activity in the application Orchid Launches Identity Audit to Illuminate the Dark Matter of Enterprise Identity Activity Data being exported</description>
</item>
<item>
<title>Orchid Island Capital Announces Fourth Quarter 2025 Results</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-announces-fourth-quarter-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-announces-fourth-quarter-2025-results</guid>
<pubDate>Thu, 29 Jan 2026 21:05:00 GMT</pubDate>
<description>VERO BEACH, Fla., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced results of operations for the three and twelve month periods ended December 31, 2025. Fourth Quarter 2025 Results Net income of $103.4 million, or $0.62 per common share, which consists of: Net interest income of $38.5 million, or $0.23 per common shareTotal expenses of $5.8 million, or $0.04 per common shareNet realized</description>
</item>
<item>
<title>Tecomet and Orchid Orthopedic Solutions to Merge</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/tecomet-and-orchid-orthopedic-solutions-to-merge</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/tecomet-and-orchid-orthopedic-solutions-to-merge</guid>
<pubDate>Wed, 14 Jan 2026 15:02:00 GMT</pubDate>
<description>Global medical manufacturing combination expected to expand complementary capabilities, strengthen supply continuity and support long-term growth Tecomet Tecomet is a global leader in the design, development and manufacture of MedTech and Aerospace & Defense products. Orchid Orchid provides solutions for procedures in major MedTech markets in the U.S. and Europe. Woburn, MA, and Mason, MI, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Tecomet and Orchid Orthopedic Solutions (“Orchid”) today announced that t</description>
</item>
<item>
<title>Orchid Security named a Cool Vendor in the 2025 Gartner® Cool Vendors™ in Identity-First Security</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-security-named-a-cool-vendor-in-the-2025-gartnerr-cool-vendorstm-in-identity-first-security</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-security-named-a-cool-vendor-in-the-2025-gartnerr-cool-vendorstm-in-identity-first-security</guid>
<pubDate>Mon, 03 Nov 2025 14:48:00 GMT</pubDate>
<description>Orchid’s orchestration-driven infrastructure approach redefines IAM, positioning it as the first-and-only identity infrastructure and a uniquely differentiated force in the identity landscapeNEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Orchid Security, the company bringing clarity and control to the complexity of enterprise identity, today announced its recognition by Gartner as a Cool Vendor in the 2025 Gartner Cool Vendors in Identity-First Security report. "These Cool Vendors demonstrate innov</description>
</item>
<item>
<title>Orchid Island Capital Announces Third Quarter 2025 Results</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-announces-third-quarter-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-announces-third-quarter-2025-results</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>VERO BEACH, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced results of operations for the three month period ended September 30, 2025. Third Quarter 2025 Results Net income of $72.1 million, or $0.53 per common share, which consists of:Net interest income of $26.9 million, or $0.20 per common shareTotal expenses of $5.4 million, or $0.04 per common shareNet realized and unrealized</description>
</item>
<item>
<title>Orchid Island Capital to Announce Third Quarter 2025 Results</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-to-announce-third-quarter-2025-results</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-island-capital-to-announce-third-quarter-2025-results</guid>
<pubDate>Mon, 06 Oct 2025 19:30:00 GMT</pubDate>
<description>VERO BEACH, Fla., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (NYSE:ORC) ("Orchid” or the "Company"), a real estate investment trust ("REIT"), today announced that it will release results for the third quarter of 2025 following the close of trading on the New York Stock Exchange on Thursday, October 23, 2025. Earnings Conference Call Details An earnings conference call and live audio webcast will be hosted Friday, October 24, 2025, at 10:00 AM ET. Participants can register and</description>
</item>
<item>
<title>Orchid Accelerates Identity Governance by Letting Applications Speak for Themselves</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/orchid-accelerates-identity-governance-by-letting-applications-speak-for-themselves</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/orchid-accelerates-identity-governance-by-letting-applications-speak-for-themselves</guid>
<pubDate>Mon, 22 Sep 2025 13:00:00 GMT</pubDate>
<description>Offers ground-truth insight straight from application code, speeding application prioritization, onboarding, and governanceAUSTIN, Texas and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Orchid Security, the company bringing clarity and control to the complexity of enterprise identity, today announced landmark capabilities to accelerate Identity Governance and Administration (IGA) adoption. The latest release of Orchid’s Identity-First Security Orchestration platform, officially SailPoint certifi</description>
</item>
<item>
<title>Press Release Feb 19 2025</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-feb-19-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-feb-19-2025-12</guid>
<pubDate>Wed, 19 Feb 2025 22:57:29 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated February 19, 2025, titled "Orchid Pharma's Alathur API facility successfully completes USFDA inspection, maintaining its position as India's only USFDA approved facility for Sterile Cephalosporins.".</description>
</item>
<item>
<title>Press Release Feb 12 2025</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-feb-12-2025-38</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-feb-12-2025-38</guid>
<pubDate>Wed, 12 Feb 2025 23:29:17 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated February 12, 2025, titled "Orchid Pharma continues on a steady growth path with strengthening market position".</description>
</item>
<item>
<title>Press Release Nov 11 2024</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-nov-11-2024-36</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-nov-11-2024-36</guid>
<pubDate>Mon, 11 Nov 2024 23:32:51 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated November 11, 2024, titled "Press Release- Orchid Pharma reportsstrong Q2 performance driven by new product milestones".</description>
</item>
<item>
<title>Press Release Aug 14 2024</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-aug-14-2024-26</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-aug-14-2024-26</guid>
<pubDate>Wed, 14 Aug 2024 17:41:20 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated August 14, 2024, titled "Orchid Pharma continuesto be on a steady and strong growth trajectory".</description>
</item>
<item>
<title>Press Release Jun 28 2024</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-jun-28-2024-14</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-jun-28-2024-14</guid>
<pubDate>Fri, 28 Jun 2024 19:42:30 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated Jun 28, 2024, titled "Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India".</description>
</item>
<item>
<title>Press Release Jun 06 2024</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-jun-06-2024-7</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-jun-06-2024-7</guid>
<pubDate>Thu, 06 Jun 2024 15:53:25 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated Jun 06, 2024, titled "Press Release- OrchidPharma receives DCGI approval for its first invented and made-in-IndiaAntibiotic Drug Combination of Cefepime and Enmetazobactam (NCE)".</description>
</item>
<item>
<title>Press Release May 23 2024</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-may-23-2024-26</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-may-23-2024-26</guid>
<pubDate>Fri, 24 May 2024 01:50:25 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated May 23, 2024, titled "Orchid Pharma announces Q4 results with 71.60% growth in annual PAT".</description>
</item>
<item>
<title>Press Release Feb 23 2024</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-feb-23-2024-3</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-feb-23-2024-3</guid>
<pubDate>Fri, 23 Feb 2024 20:10:20 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated February 23, 2024, titled "Orchid Pharma's 'Exblifep' receives USFDA approval: A new milestone for India's Pharmaceutical industry".</description>
</item>
<item>
<title>Press Release Jan 29 2024</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-jan-29-2024-23</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-jan-29-2024-23</guid>
<pubDate>Mon, 29 Jan 2024 22:52:36 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange regarding a press release dated January 29, 2024, titled "Press release titled as "Orchid Pharma's 'Exblifep' granted European Medicines Agency approval - A landmark achievement for India's pharmaceutical Industry".</description>
</item>
<item>
<title>Press Release Sep 12 2023</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-sep-12-2023-10</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-sep-12-2023-10</guid>
<pubDate>Tue, 12 Sep 2023 19:28:45 GMT</pubDate>
<description>Announcement under regulation 30 of SEBI(LODR) Regulations, 2015</description>
</item>
<item>
<title>Press Release Dec 01 2022</title>
<link>https://6ix.com/company/orchid-pharma-limited/news/press-release-dec-01-2022-16</link>
<guid isPermaLink="true">https://6ix.com/company/orchid-pharma-limited/news/press-release-dec-01-2022-16</guid>
<pubDate>Fri, 02 Dec 2022 03:03:00 GMT</pubDate>
<description>Orchid Pharma Limited has informed the Exchange about press release dated 01-Dec-2022 titled Corrigendum to Press Release Dated December 01, 2022</description>
</item>
</channel>
</rss>